false
Hamburger Menu
Catalog
IASLC Lung Cancer News (ILCN), May 2022
IASLC Lung Cancer News (ILCN), May 2022
ILCN | English | 2022
Create Account
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
IASLC Lung Cancer News (ILCN), May 2022
Table of Contents
Alternative Dosing Strategies for Immune Checkpoint Inhibitors
US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective
Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes
Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System
Renowned Researcher Fred Hirsch Delivers 2022 Heine H. Hansen Award Lecture
In Brief for May 25, 2022
Financial Toxicity of Lung Cancer in the Netherlands
As Treatment Options in Lung Cancer Have Expanded, so Have Costs
Small, High PLCG2-Expressing Intratumoral Cells May Drive Metastasis
COAST Data Support Further Research of Immunotherapy Combinations
IASLC Responds to Call for Evidence
In Brief for May 11, 2022
About ILCN
IASLC Lung Cancer News (ILCN) is the offical news source of the only global association dedicated to the multidisciplinary study of lung cancer, published bimonthly by the International Association for the Study of Lung Cancer (IASLC).
Click here to link to
Submission Guidelines
.
×
IASLC Lung Cancer News (ILCN), May 2022 Course List
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English